PARSLOW JAMES F 4
4 · Xenetic Biosciences, Inc. · Filed Apr 23, 2026
Research Summary
AI-generated summary of this filing
Xenetic (XBIO) Interim CEO/CFO James Parslow Receives Award
What Happened
- James F. Parslow, Interim CEO and CFO of Xenetic Biosciences (XBIO), was granted 100,000 restricted shares on April 21, 2026. The shares were issued at $0.00 (no cash paid) as an award/grant (Form 4 code A).
Key Details
- Transaction date: 2026-04-21; Form filed: 2026-04-23 (filed timely).
- Grant size and price: 100,000 shares, $0.00 per share (total cash paid $0).
- Vesting (footnote F1): 7,000 shares vest immediately on grant date; the remaining 93,000 shares vest in three equal installments of 31,000 shares on each of the 1st, 2nd and 3rd anniversaries of April 21, 2026.
- Shares owned after transaction: Not disclosed in the information provided on this filing.
- Transaction type: Award/Grant (code A) — a compensation event, not a market purchase or sale.
Context
- Restricted stock grants are compensation and typically vest over time; they do not by themselves indicate a buy/sell signal from the insider. This filing reports the grant and the vesting schedule; any future sales or exercises would appear in later filings.
Insider Transaction Report
Form 4
PARSLOW JAMES F
Interim CEO and CFO
Transactions
- Award
Common Stock
[F1]2026-04-21+100,000→ 100,000 total
Footnotes (1)
- [F1]This represents a restricted stock grant ("RSG"). The shares represented by the RSG will vest and become exercisable as follows: 7,000 shares shall vest on the date of grant and one-third of the remaining (93,000) shares shall vest on each of the first, second and third anniversaries of April 21, 2026.
Signature
/s/ James Parslow|2026-04-23